TY - JOUR
T1 - Cancer and All-cause Mortality in Bladder Cancer Patients Undergoing Radical Cystectomy
T2 - Development and Validation of a Nomogram for Treatment Decision-making
AU - Williams, Stephen B.
AU - Huo, Jinhai
AU - Chu, Yiyi
AU - Baillargeon, Jacques G.
AU - Daskivich, Timothy
AU - Kuo, Yong Fang
AU - Kosarek, Christopher D.
AU - Kim, Simon P.
AU - Orihuela, Eduardo
AU - Tyler, Douglas S.
AU - Freedland, Stephen J.
AU - Kamat, Ashish M.
N1 - Publisher Copyright:
© 2017 Elsevier Inc.
PY - 2017/12
Y1 - 2017/12
N2 - Objective To develop and validate a nomogram assessing cancer and all-cause mortality following radical cystectomy. Given concerns regarding the morbidity associated with surgery, there is a need for incorporation of cancer-specific and competing risks into patient counseling and recommendations. Materials and Methods A total of 5325 and 1257 diagnosed with clinical stage T2-T4a muscle-invasive bladder cancer from January 1, 2006 to December 31, 2011 from Surveillance, Epidemiology, and End Results-Medicare and Texas Cancer Registry-Medicare linked data, respectively. Cox proportional hazards models were used and a nomogram was developed to predict 3- and 5-year overall and cancer-specific survival with external validation. Results Patients who underwent radical cystectomy were mostly younger, male, married, non-Hispanic white and had fewer comorbidities than those who did not undergo radical cystectomy (P <.001). Married patients, in comparison with their unmarried counterparts, had both improved overall (hazard ratio 0.76; 95% confidence interval 0.70-0.83, P <.001) and cancer-specific (hazard ratio 0.76; 95% confidence interval 0.68-0.85, P <.001) survival. A nomogram developed using Surveillance, Epidemiology, and End Results-Medicare data, predicted 3- and 5-year overall and cancer-specific survival rates with concordance indices of 0.65 and 0.66 in the validated Texas Cancer Registry-Medicare cohort, respectively. Conclusion Older, unmarried patients with increased comorbidities are less likely to undergo radical cystectomy. We developed and validated a generalizable instrument that has been converted into an online tool (Radical Cystectomy Survival Calculator), to provide a benefit-risk assessment for patients considering radical cystectomy.
AB - Objective To develop and validate a nomogram assessing cancer and all-cause mortality following radical cystectomy. Given concerns regarding the morbidity associated with surgery, there is a need for incorporation of cancer-specific and competing risks into patient counseling and recommendations. Materials and Methods A total of 5325 and 1257 diagnosed with clinical stage T2-T4a muscle-invasive bladder cancer from January 1, 2006 to December 31, 2011 from Surveillance, Epidemiology, and End Results-Medicare and Texas Cancer Registry-Medicare linked data, respectively. Cox proportional hazards models were used and a nomogram was developed to predict 3- and 5-year overall and cancer-specific survival with external validation. Results Patients who underwent radical cystectomy were mostly younger, male, married, non-Hispanic white and had fewer comorbidities than those who did not undergo radical cystectomy (P <.001). Married patients, in comparison with their unmarried counterparts, had both improved overall (hazard ratio 0.76; 95% confidence interval 0.70-0.83, P <.001) and cancer-specific (hazard ratio 0.76; 95% confidence interval 0.68-0.85, P <.001) survival. A nomogram developed using Surveillance, Epidemiology, and End Results-Medicare data, predicted 3- and 5-year overall and cancer-specific survival rates with concordance indices of 0.65 and 0.66 in the validated Texas Cancer Registry-Medicare cohort, respectively. Conclusion Older, unmarried patients with increased comorbidities are less likely to undergo radical cystectomy. We developed and validated a generalizable instrument that has been converted into an online tool (Radical Cystectomy Survival Calculator), to provide a benefit-risk assessment for patients considering radical cystectomy.
UR - http://www.scopus.com/inward/record.url?scp=85030464709&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85030464709&partnerID=8YFLogxK
U2 - 10.1016/j.urology.2017.08.024
DO - 10.1016/j.urology.2017.08.024
M3 - Article
C2 - 28847688
AN - SCOPUS:85030464709
SN - 0090-4295
VL - 110
SP - 76
EP - 83
JO - Urology
JF - Urology
ER -